- Home
- AVK vs PACB Comparison
AVK vs PACB Comparison
Compare AVK & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVK | PACB |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.9M | 486.1M |
| IPO Year | 2003 | 2010 |
Fundamental Metrics
Financial Performance| Metric | AVK | PACB |
|---|---|---|
| Price | $12.51 | $1.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.08 |
| AVG Volume (30 Days) | 154.6K | ★ 6.8M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $12.46 |
| Revenue Next Year | N/A | $12.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $9.75 | $0.85 |
| 52 Week High | $13.10 | $2.73 |
Technical Indicators
Market Signals| Indicator | AVK | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 39.17 |
| Support Level | $12.00 | $1.44 |
| Resistance Level | $12.87 | $1.70 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 8.70 | 27.78 |
Price Performance
Historical ComparisonAbout AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.